CD40L-Dependent Pathway Is Active at Various Stages of Rheumatoid Arthritis Disease Progression

• Published in: The Journal of immunology (1950) 2017-06, Vol.198 (11), p.4490-4501
• Main Authors: Guo, Yanxia, Walsh, Alice M, Fearon, Ursula, Smith, Malcolm D, Wechalekar, Mihir D, Yin, Xuefeng, Cole, Suzanne, Orr, Carl, McGarry, Trudy, Canavan, Mary, Kelly, Stephan, Lin, Tai-An, Liu, Xuejun, Proudman, Susanna M, Veale, Douglas J, Pitzalis, Costantino, Nagpal, Sunil
• Format: Article
• Language: English
• Subjects: Adult; Aged; Arthralgia; Arthralgia - immunology; Arthralgia - physiopathology; Arthritis - immunology; Arthritis, Rheumatoid - immunology; Arthritis, Rheumatoid - physiopathology; Autoimmune diseases; B-Lymphocytes - drug effects; B-Lymphocytes - immunology; Biopsy; CD4-Positive T-Lymphocytes - immunology; CD40 antigen; CD40 Antigens - deficiency; CD40 Antigens - genetics; CD40 Antigens - immunology; CD40 Antigens - metabolism; CD40 Ligand - genetics; CD40 Ligand - immunology; CD40 Ligand - metabolism; CD40 Ligand - pharmacology; CD40L protein; Chemical compounds; Citrulline; Dendritic cells; Dendritic Cells - immunology; Dendritic Cells - physiology; Disease; Disease Progression; Female; Genes; Healthy Volunteers; Humans; Lymphocyte Activation; Lymphocytes B; Male; Middle Aged; Rheumatoid arthritis; Signal Transduction; Synovial Fluid - cytology; Synovial Fluid - immunology; Tissues; Transcriptome
• ISSN: 0022-1767; 1550-6606
• DOI: 10.4049/jimmunol.1601988

The inflammatory CD40-CD40L pathway is implicated in various autoimmune diseases, but the activity status of this pathway in various stages of rheumatoid arthritis (RA) progression is unknown. In this study, we used gene signatures of CD40L stimulation derived from human immature dendritic cells and naive B cells to assess the expression of CD40-downstream genes in synovial tissues from anti-citrullinated protein Ab-positive arthralgia, undifferentiated arthritis (UA), early RA, and established RA cohorts in comparison with healthy donors. Interestingly, the expression of and active full-length was increased in the disease tissues, whereas that of a dominant-negative isoform was decreased. Gene set variation analysis revealed that CD40L-responsive genes in immature dendritic cells and naive B cells were significantly enriched in synovial tissues from UA, early RA, and established RA patients. Additionally, CD40L-induced naive B cell genes were also significantly enriched in synovial tissues from arthralgia patients. In our efforts to characterize downstream mediators of CD40L signaling, we have identified and as novel components of the pathway. In conclusion, our data suggest that therapeutic CD40-CD40L blocking agents may prove efficacious not only in early and established RA, but also in inhibiting the progression of the disease from arthralgia or UA to RA.